International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases
October 09 2017 - 8:30AM
InvestorsHub NewsWire
CARLSBAD, Calif Oct. 9, 2017 -- InvestorsHub
NewsWire -- International Stem Cell Corporation (OTCQB:
ISCO) (www.internationalstemcell.com)
("ISCO" or "the Company"), a California-based clinical stage
biotechnology company that develops novel stem cell-based therapies
and biomedical products, announced today a significant advancement
in 3D bioprinting of liver tissue.
ISCO’s R&D team has developed a 3D bioprinter which utilizes
proprietary liver progenitor cells (LPC), which differentiate into
cholangiocytes, hepatocytes and stellate cells. Once 3D
liver-like structures are produced from the LPC, they are expected
to provide a treatment for various liver diseases once transplanted
into the damaged liver. The LPC can be derived from any kind of
pluripotent stem cells, including human embryonic, induced
pluripotent, or parthenogenetic stem cells, via ISCO’s proprietary
highly efficient and scalable differentiation method.
"I’m excited to announce that we have developed a new efficient
technology to produce 3D liver tissue, which may be able to replace
damaged tissue to restore liver functions. Additionally, the
developed liver tissue potentially can be used not only in
liver treatment, but also in drug discovery as a model for drug
screening, which opens up a potential multi-billion market for
ISCO” commented Russell Kern, PhD., Executive Vice President and
Chief Scientific Officer of ISCO. “We have already developed a
master cell bank of the liver progenitor cells and, we are
proceeding to test safety and efficacy of the cells in various
models of liver diseases like liver cirrhosis and fibrosis” he
continued.
According to the American Liver Foundation, approximately 17,000
patients are on the U.S. liver transplant waiting list with only
6,000 liver transplants performed each year. Currently, there are
no alternatives available for patients in need of a liver
transplant other than to join the waiting list. Cirrhosis is
the end stage in patients who have chronic progressive liver
disease. While liver transplantation is a viable treatment option
for these candidates, increasing waiting times for organ
transplantation has led to the deaths of nearly 17% of those who
were on the waiting list.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the
therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of human pluripotent stem
cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for
millions of individuals of differing genders, ages and racial
background with minimal immune rejection after transplantation.
hpSCs offer the potential to create the first true stem cell bank,
UniStemCell™. ISCO also produces and markets specialized cells and
growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology (www.lifelinecelltech.com),
and stem cell-based skin care products through its subsidiary
Lifeline Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please
click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page for company updates and industry
related news, visit: www.facebook.com/InternationalStemCellCorporation
Safe harbor statement
Statements pertaining to anticipated developments, expected results
and timing of clinical studies, progress of research and
development initiatives, potential applications for ISC-hpNSC® and
other opportunities for the company and its subsidiaries, along
with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
regulatory approvals, need and ability to obtain future capital,
application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company's business,
particularly those mentioned in the cautionary statements found in
the company's Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update
forward-looking statements.
International Stem Cell Corporation
Dr. Russell Kern
EVP, Chief Scientific Officer
(760)940-6383
ir@intlstemcell.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Apr 2023 to Apr 2024